First-line atezolizumab treatment significantly improves overall survival in patients with NSCLC and not eligible for a platinum-containing regimen

Many patients with advanced-stage lung cancer cannot tolerate standard platinum-based chemotherapy. As a late-breaking Siow Ming Lee presents the first randomized trial to show that first-line atezolizumab treatment significantly improves overall survival compared to single agent chemotherapy for these poor prognosis patients with no EGFR and ALK alterations.